Iovance Biotherapeutics (IOVA) AGM 2026 summary

Opening remarks and agenda

• Meeting convened virtually with directors, executive officers, and the independent auditor present.

• Inspector of Elections confirmed quorum and explained online voting procedures.

• Proxy statement and meeting notice distributed to shareholders as of April 15, 2026.

Board and executive committee updates

• Election of nominated directors to serve until the 2027 annual meeting approved.

Shareholder proposals

• Advisory approval of executive compensation passed.

• Annual frequency for future executive compensation votes approved.

• Ratification of Ernst & Young LLP as independent auditor for 2026 approved.

• Amendment to increase shares in the 2020 Employee Stock Purchase Plan approved.

• Amendment to increase authorized common stock from 500M to 650M shares approved.